NICE has said it expects to evaluate dozens of potential treatments for Alzheimer’s disease over the next few years. Elisabeth Mahase examines what we know about these drugs This year the National ...
A groundbreaking study from the University of California has hinted that following a keto diet might just be the secret to ...
New research from Scripps Research links Alzheimer’s disease and alcohol use disorder, showing similar gene expression ...
Longer-term, Eisai and Biogen are hoping for further evidence to support Leqembi from the phase 3 AHEAD 3-45 trial, which ...
Six years after his Alzheimer’s diagnosis, 90-year-old Zelik Bocknek (Zel) refuses to slow down — and he believes his active ...
Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.
The Hearty Soul on MSN6h
These Nutrients Are Lower In Alzheimer's Patients, StudyAlzheimer's disease is a progressive neurodegenerative disease that affects millions of people worldwide. Oxidative stress ...
Neurologist Dona Murphey, the founder of website PrognosUs, hopes her platform can give caregivers a place to find support in ...
John Reichart says he's been assembling Christmas decor in his garage since September. On Thursday, the final lawn ornament ...
Newsweek on MSN45m
Alcohol Addiction Can Trigger Onset and Acceleration of Alzheimer'sThe onset of symptoms of Alzheimer's disease can occur and worsen quicker in people that also have an alcohol use disorder (AUD), a new study has revealed. According to the scientists based at Scripps ...
US pharmaceutical company Eli Lilly brings Memory Cafe to its booth at the ongoing 7th CIIE in collaboration with the ...
Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback